| 前收市價 | 1.7000 |
| 開市 | 1.9900 |
| 買盤 | 0.2500 |
| 賣出價 | 2.5000 |
| 拍板 | 150.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 1.5500 - 2.2200 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 149 |
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
BloombergBioNTech Cancer Drug Licensed From MediLink Faces FDA Delay
(Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanS&P 500 Hits 30th Record of 2024 as Megacaps Rally: Markets WrapThese Are the World’s Most Expensive Cities for Expats in 2024Hedge Funds’ Secret Weapon to Fight the SEC Lives in TexasHow the US Mo
Motley FoolWhy Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?
